VitaStem-Hematopoietic Stem Cell Rejuvenation

Vitastem-hematopoietic Stem Cell Rejuvenation

VitaSTEM

Aging

Unlocking longevity through in-situ Hematopoietic Stem Cell Rejuvenation using combined modulation of aging-disrupted pathways identified by publicly available and proprietary single-cell datasets from young and old human populations. Stem-cell exhaustion is a key hallmark of aging, contributing to impaired tissue repair, immune dysfunction, and systemic frailty. In this project, we took a novel approach to this challenge—rather than replacing aged blood-forming stem cells (HSCs) through transplantation, the project seeks to rejuvenate the body’s own stem cells in situ. We have analysed nearly 850,000 single-cell transcriptomes from healthy donors aged 23 to 91 from publically available and proprietary datasets, generating a high-resolution atlas of hematopoietic aging. The data reveal consistent age-related molecular signatures: younger HSCs show elevated expression of DNA repair and mitochondrial genes, while older cells exhibit ferroptosis drivers, inflammatory signaling (notably TNF and IL-17), and upregulation of CCR9 and long non-coding RNAs. These findings were confirmed in both circulating and bone marrow-derived HSCs, reinforcing their potential as biomarkers and intervention targets. In conclusion, we have identified a list of target genes, which can be used as a intervention for hematopoietic stem cell rejuvenation studies. The key insight is that we are targeting multiple aging mechanisms simultaneously - transcriptional stress responses, epigenetic regulation, and protein homeostasis. Classic damage repair thinking applied to the molecular level. This multi-pronged approach could achieve the robust rejuvenation that single interventions miss.

Description

Stem-cell exhaustion is a key hallmark of aging, contributing to impaired tissue repair, immune dysfunction, and systemic frailty. In this project, we took a novel approach to this challenge—rather than replacing aged blood-forming stem cells (HSCs) through transplantation, the project seeks to rejuvenate the body’s own stem cells in situ. We have analysed nearly 850,000 single-cell transcriptomes from healthy donors aged 23 to 91 from publically available and proprietary datasets, generating a high-resolution atlas of hematopoietic aging. The data reveal consistent age-related molecular signatures: younger HSCs show elevated expression of DNA repair and mitochondrial genes, while older cells exhibit ferroptosis drivers, inflammatory signaling (notably TNF and IL-17), and upregulation of CCR9 and long non-coding RNAs. These findings were confirmed in both circulating and bone marrow-derived HSCs, reinforcing their potential as biomarkers and intervention targets. In conclusion, we have identified a list of target genes, which can be used as a intervention for hematopoietic stem cell rejuvenation studies. The key insight is that we are targeting multiple aging mechanisms simultaneously - transcriptional stress responses, epigenetic regulation, and protein homeostasis. Classic damage repair thinking applied to the molecular level. This multi-pronged approach could achieve the robust rejuvenation that single interventions miss.

Team

Owner

Owner

Owner

Owner

Owner

Experiment Cost

$0.00

Project Score

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

Project Progress

All updates

All categories

Timeline

Vitastem-hematopoietic Stem Cell Rejuvenation

VitaSTEM

Aging

Description

Team

Owner

Owner

Owner

Owner

Owner

Experiment Cost

$0.00

Project Score

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

Project Progress

All updates

All categories

Timeline

Rationale

The project has completed extensive computational and bioinformatics work (~850,000 single-cell transcriptomes analyzed, AI/ML-assisted GRN modeling, differential gene expression analysis) but has conducted zero wet-lab experiments. All in vitro, advanced in vitro, and in vivo studies are explicitly described as "planned" or "not yet used." The absence of any empirical laboratory data — no binding assays, no cell-based assays, no functional validation of any kind — firmly places this project at TRL 1 (Concept Alone).

Assessment

Low Confidence

RecommendationPROMOTE

Total Score3.75

Overall Assessment

The VitaStem HSC Rejuvenation project scores 3.75 out of 5.0 at TRL 1, reflecting a scientifically well-motivated but entirely pre-experimental program. The strongest dimension is therapeutic relevance (weighted score 2.40/3.00): the biological rationale for HSC rejuvenation is compelling, the computational foundation is substantial (~850K transcriptomes analyzed), and the identified targets align with known aging biology. However, the complete absence of any wet-lab validation data is a notable limitation even for TRL 1. Therapeutic optionality is solid (0.60/0.75), as HSC rejuvenation has broad implications across hematology, immunology, and aging medicine, and the multi-modal intervention framework provides flexibility. The weakest dimension is intellectual property (0.75/1.25): while the combinatorial approach may be novel, many individual targets and drugs are well-established in the literature, no IP has been filed, and reliance on public datasets and known compounds creates prior art exposure. Overall, this is a promising early-stage concept with strong scientific grounding that needs to urgently advance to experimental validation and secure IP protection to realize its potential. The proposed $100K budget and 12-month timeline for in vitro validation represent a reasonable next step to de-risk the program.

Weighted Score

Therapeutic Relevance

The proposed mechanism is scientifically plausible and well-grounded. HSC aging is a biologically validated driver of immune decline, anemia, and hematologic malignancies. The project leverages robust single-cell transcriptomic analysis (~850,000 transcriptomes across ages 23–91) to identify differentially expressed genes with very high statistical significance (adjusted p-values <10^-200). The targets identified (NR4A1/2, UHRF1, CD38, CCR9, etc.) are biologically relevant to known aging pathways (epigenetic drift, NAD+ depletion, inflammatory signaling, myeloid skewing). The multi-modal intervention strategy targeting transcriptional stress responses, epigenetic regulation, and protein homeostasis simultaneously is scientifically sound. However, the score is not a 5 because: (1) all evidence is computational/bioinformatics-derived with zero experimental validation; (2) the AubrAI-generated hypothesis, while interesting, is AI-generated and unvalidated; (3) no specific gene names or quantitative results are disclosed in the primary document, limiting independent assessment of target quality; and (4) the leap from differentially expressed genes to therapeutic targets requires functional validation that has not yet begun.

Therapeutic Optionality

The concept demonstrates strong therapeutic optionality. HSC rejuvenation could address multiple therapeutic areas: age-related immune decline, anemia, susceptibility to infections, myelodysplastic syndromes, leukemia prevention, and broader healthy aging/frailty. The multi-modal intervention framework (mRNA, siRNA, CRISPR, small molecules, gene therapy, nanoparticle delivery) provides significant flexibility in modality selection. The identified targets span diverse biological mechanisms (epigenetic, metabolic, inflammatory, differentiation), offering multiple independent intervention points. The platform approach (scRNA-seq + AI/ML GRN analysis) could potentially be applied to other stem cell types beyond HSCs. One target (TPSB2/TPSAB1) already has an FDA-approved drug (cromolyn sodium) for potential repurposing. The score is not a 5 because the concept is still narrowly focused on HSCs specifically, and the breadth of application remains theoretical without any experimental proof-of-concept.

Intellectual Property

The IP position is moderate with both strengths and risks. Strengths: the specific combination of targets identified through proprietary computational analysis and the multi-modal temporal coordination strategy could be novel and patentable; the use of proprietary datasets alongside public data adds some differentiation; the specific intervention protocol (phased multi-target approach) may be patentable as a method. Risks: (1) no patents have been filed or granted yet — IP is entirely aspirational at this stage; (2) many individual targets (CD38, RhoA, NR4A family, rapamycin/mTOR) are well-known in the aging and hematopoiesis literature, creating significant prior art concerns; (3) the computational analysis relies partly on publicly available scRNA-seq datasets, limiting data exclusivity; (4) several proposed small molecules (fasudil, rapamycin, cromolyn sodium) are already known/approved drugs; (5) competitors in the HSC rejuvenation space (academic labs, biotech companies) are actively pursuing similar targets; (6) the AubrAI tool's contribution to the hypothesis raises questions about inventorship and IP ownership. The combination approach may be novel, but individual components face substantial prior art.